scanance.
Sign inGet Premium
PM

Philip Morris International Inc.

PMConsumer DefensiveNASDAQ

Tobacco · Last scanned Jun 3, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$40.65B
+7.3% YoY
Net Income
$11.35B
+60.8% YoY
EBITDA
$17.46B
+10.9% YoY
Free Cash Flow
$8.58B

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Philip Morris International Inc.

Philip Morris International Inc. operates in the Tobacco space. Philip Morris International Inc. The company carries a $270.66B market cap, placing it firmly in the mega-cap category. operates as a tobacco company.

Key stats
Market Cap$270.66B
P/E (TTM)24.46
Fwd P/E19.01
EPS$7.10
Beta0.39
52W Change-3.9%
Dividend Yield3.39%
Analysis

The company holds $5.46B in cash, though total debt stands at $51.98B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow comes in at $8.58B, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on assets of 15.5% further supports the picture of efficient asset utilization. Revenue has grown from $31.76B (2022) to $40.65B (2025), reflecting a 28% increase over the period.

The relatively low beta of 0.39 suggests PM is a less volatile holding compared to the broader index. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Philip Morris International Inc. and its sector.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms